Author of

• 32243

  +

  EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Treatment in the Real World - Support, Survivorship, Systems Research
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32291

    +

    EP1.16-14 - Efficacy of First-Line Continuous Maintenance of Pemetrexed Therapy for Lung Adenocarcinoma When Administered at Routine or Extended Intervals (Now Available) (ID 1822)

    08:00 - 18:00  |  Author(s): Shishi Cheng
    • Abstract
    • Slides

    Background
    

    Background: Lung cancer is the most common cancer and the leading cause of death due to cancer worldwide , The benefit of maintenance therapy with pemetrexed with or without antiangiogenesis inhibitors has been observed in previous studies. However, continuous maintenance therapy with the pemetrexed-antiangiogenesis combination has rarely been evaluated in the real world setting. In real life, patients may not receive maintenance therapy or may receive delayed maintenance therapy (stopping interval of >21 days) owing to many factors. The purpose of this study was to obtain real-world data on the maintenance of local progressive and metastatic non-squamous non-small cell lung cancer (NSCLC) in first-line patients treated with or without pemetrexed antiangiogenesis, and to evaluate the effect of extended interention on clinical outcomes.

    Method
    

    Methods: 168 patients with stage IIIB or IV lung adenocarcinoma who had not been treated previously received pemetreplatin-induced chemotherapy with or without anti-angiogenesis inhibitors (bevacizumab or rh-endostatin) every 3 weeks for a course of 4-6 weeks.The efficacy and safety of 112 patients without progression after induction chemotherapy were analyzed.

    Result
    

    Results: 70 of the 112 patients received continuous maintenance therapy, with or without an anti-angiogenesis inhibitor, until the disease progressed.42 patients did not receive continuous maintenance therapy.The median duration of maintenance therapy was 4(range 1-26);The median interval of each maintenance treatment cycle was 40 days (ranged from 21 to 77 days).The optimal objective efficiency of maintenance group and non-maintenance group was 48.6% and 33.3%, respectively.At an average follow-up of 14.6 months, the median progression-free survival was 11.5 months (95% CI: 9.8 -13.2 months) and 6.8 months (95% CI :5.4-8.2 months,p < 0.001), and the median overall survival was 40.1 months (22.5 - 57.7 months) and 18.0 months (10.4-25.6 months,p = 0.001) in the maintenance and non-maintenance groups, respectively.The most common grade 3-4 adverse event in both groups was neutropenia (18.6% vs. 19.0%).

    Conclusion
    

    Conclusion: prolongation of maintenance time is feasible, and for patients without progression after first-line induction therapy for lung adenocarcinoma, continuous maintenance therapy with or without combination of pemetrexed with anti-angiogenesis is essential for survival benefits.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.